Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) EPS (Weighted Average and Diluted) (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with -$0.34 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 160.71% to -$0.34 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.9, a 68.2% decrease, with the full-year FY2024 number at $2.19, down 33.64% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.34 for Q3 2025 at Usana Health Sciences, down from $0.52 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.87 in Q3 2021 to a low of -$0.34 in Q3 2025.
  • A 5-year average of $0.9 and a median of $0.86 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 41.67% in 2021, then plummeted 160.71% in 2025.
  • Usana Health Sciences' EPS (Weighted Average and Diluted) stood at $1.36 in 2021, then tumbled by 51.47% to $0.66 in 2022, then soared by 31.82% to $0.87 in 2023, then plummeted by 73.56% to $0.23 in 2024, then tumbled by 247.83% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for USNA's EPS (Weighted Average and Diluted) are -$0.34 (Q3 2025), $0.52 (Q2 2025), and $0.49 (Q1 2025).